首页> 外文期刊>Laboratory investigation >MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas
【24h】

MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas

机译:MS-MLPA:一种可靠的替代实验室分析方法,用于可靠,可靠和半定量检测神经胶质瘤中MGMT启动子的超甲基化

获取原文
           

摘要

Expression of the DNA repair protein O6-alkylguanine-DNA-alkyltransferase (AGT), encoded by the O6-methylguanine (O6-mG) -DNA-methyltransferase (MGMT) DNA repair gene, results in resistance to alkylating agents, and hypermethylation of the MGMT promoter is associated with chemosensitivity as it prevents AGT expression. As the interpretation of the results of immunohistochemistry to evaluate AGT expression proved to be difficult, the aim of our present study is to establish a feasible, reliable, and robust method for MGMT promoter hypermethylation testing that can be easily implemented in a diagnostic setting and is applicable to routinely processed tissue. MGMT hypermethylation analysis using methylation-specific (MS-) multiplex ligation-dependent probe amplification (MLPA) was performed on 62 glioma samples of 55 individual tumors (including 12 cell lines) and compared to the more conventionally used, but improved, MS-polymerase chain reaction (PCR). In contrast to MS-PCR, MS-MLPA (i) is not based on bisulfite conversion of unmethylated cytosines (a somewhat troublesome step in MS-PCR), (ii) provided methylation status of all samples, (iii) proved to be semiquantitative, (iv) can be used to evaluate methylation status of multiple sequences (CpG dinucleotides) simultaneously, and (v) allows for a combined copy number detection and methylation specific analysis. The potential therapeutic value of MGMT hypermethylation evaluation using MS-MLPA was shown in a group of 20 glioblastoma patients receiving temozolomide chemotherapy. We conclude that MS-MLPA is a robust and reliable method that can be easily applied to differently processed tissues, including those fixed in formalin and embedded in paraffin. The semiquantitative aspect of MS-MLPA may prove to be of great value, especially in predicting response to alkylating agents, not only for gliomas as evaluated in this study but also for tumors in general.
机译:由O6-甲基鸟嘌呤(O6-mG)-DNA-甲基转移酶(MGMT)DNA修复基因编码的DNA修复蛋白O6-烷基鸟嘌呤-DNA-烷基转移酶(AGT)的表达导致其对烷基化剂的抗性和甲基化MGMT启动子与化学敏感性相关,因为它阻止AGT表达。由于难以解释用于评估AGT表达的免疫组化结果,因此,本研究的目的是建立一种可行,可靠且可靠的MGMT启动子超甲基化测试方法,该方法可在诊断环境中轻松实施,并且适用于常规处理的组织。使用甲基化特异性(MS-)多重连接依赖性探针扩增(MLPA)进行MGMT高度甲基化分析,对55个单个肿瘤(包括12个细胞系)的62个神经胶质瘤样本进行了分析,并与更常规使用但经过改进的MS聚合酶进行了比较连锁反应(PCR)。与MS-PCR相比,MS-MLPA(i)不是基于未甲基化的胞嘧啶的亚硫酸氢盐转化(在MS-PCR中是一个比较麻烦的步骤),(ii)提供了所有样品的甲基化状态,(iii)被证明是半定量的,(iv)可用于同时评估多个序列(CpG二核苷酸)的甲基化状态,并且(v)允许组合的拷贝数检测和甲基化特异性分析。使用MS-MLPA评估MGMT甲基化水平的潜在治疗价值在接受替莫唑胺化疗的20例胶质母细胞瘤患者中显示。我们得出的结论是,MS-MLPA是一种可靠且可靠的方法,可以轻松应用于不同处理的组织,包括固定在福尔马林中和包埋在石蜡中的组织。 MS-MLPA的半定量方面可能被证明具有很大的价值,特别是在预测对烷化剂的反应方面,不仅对于本研究评估的神经胶质瘤,而且对于一般的肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号